Minerva Neurosciences (NERV) Stock: Buy, Sell, or Hold?
NERV - Minerva Neurosciences, Inc
$3.28
0.05 (1.55%)
▲
5d:
-3.53%
30d:
-26.79%
90d:
-33.33%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
30d
Get Alerted When NERV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NERV shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NERV shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NERV is currently trading at $3.28, which is considered oversold relative to its 30-day fair value range of $3.41 to $4.64.
Technical Outlook: Technically, NERV is in a downtrend. Immediate support is located at $3.17, while resistance sits at $3.86.
Market Sentiment: NERV scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $10.33 (+215.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NERV is in a downtrend. Immediate support is located at $3.17, while resistance sits at $3.86.
Market Sentiment: NERV scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $10.33 (+215.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.41 -
$4.64
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 215.0% below Wall St target ($10.33)
- CAUTION: Bottoming setup, but lagging the sector by 44% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$3.41 -
$4.64
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.58
(17.8%)
Support & Resistance Levels
Support Level
$3.17
Resistance Level
$3.86
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.81
Wall Street Target
$10.33
(+215.0%)
Share & Embed Analysis
Last updated: October 03, 2026 11:51 PM ET
Data refreshes hourly during market hours. Next update: 12:51 AM
Data refreshes hourly during market hours. Next update: 12:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NERV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 52 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$107 | 67 BUY |
